4-O-(2,5-dioxopyrrolidin-1-yl) 1-O-[(19S)-19-ethyl-19-hydroxy-14,18-dioxo-17-oxa-3-azapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl] butanedioate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-O-(2,5-dioxopyrrolidin-1-yl) 1-O-[(19S)-19-ethyl-19-hydroxy-14,18-dioxo-17-oxa-3-azapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaen-7-yl] butanedioate
• 化学式: C₂₉H₂₄N₂O₁₀
• 分子量: 560.5
• InChiKey: AMUFTVWSWCOADH-MPRLKSRNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  41
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  167
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• US20140256623A1
  申请人：——

  公开号：US20140256623A1

  公开（公告）日：2014-09-11
• TRANSMUCOSAL DELIVERY OF PHARMACEUTICAL ACTIVE SUBSTANCES
  申请人：ANYGEN CO., LTD.

  公开号：US20170252453A9

  公开（公告）日：2017-09-07

  Provided is a conjugate including a pharmacologically active substance covalently bound to chitosan or its derivative and a method for transmucosal delivery of a pharmacologically active substance using the same. Specifically a conjugate includes a pharmacologically active substance covalently bound via a linker to chitosan; and a pharmaceutical composition for transmucosal administration of a drug includes the aforementioned conjugate and a pharmaceutically acceptable carrier. Further provided is a method for in vivo delivery of a pharmacologically active substance via a transmucosal route, by covalent binding of the active substance with chitosan or its derivative via a linker. The conjugate in accordance with the present invention exhibits excellent absorption rate and biocompatibility in biological mucous membranes, particularly mucous membranes of the alimentary canal (especially the gastrointestinal tract), in vivo degradability, and superior bioavailability even with oral administration, thus enabling treatment of diseases via oral administration of a drug.